Plasma matrix metalloproteinase-9 and ACE-inhibitor-induced improvement of urinary albumin excretion in non-diabetic, microalbuminuric subjects

Ruud M. A. Van de Wal, Pim Van der Harst, Wim B. M. Gerritsen, Fal Van der Horst, Thijs H. W. Plokker, Ron T. Gansevoort, Wiek H. van Gilst, Adriaan A. Voors*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

4 Citaten (Scopus)


Introduction. Elevated plasma matrix metalloproteinase-9 (MMP-9) levels have been suggested to precede the development of microalbuminuria. As angiotensin-converting enzyme (ACE) inhibitors effectively reduce urinary albumin excretion (UAE), in the present study we have investigated the potential association of plasma MMP-9 levels with UAE and treatment effects of ACE-inhibition.

Material and methods. In a placebo-controlled randomised trial we determined plasma MMP-9 levels at baseline and after three months of randomisation to either placebo (n=202) or fosinopril (20 mg/day, n=204) treatment.

Results. Baseline plasma MMP-9 levels were not related to baseline UAE (r=-0.008, p=0.871). Three months of fosinopril treatment effectively reduced UAE compared to placebo treatment (-10.4 +/- 2.4 vs. 1.8 +/- 1.3 mg/24 hours, p

Conclusion. The effective reduction of UAE with fosinopril was not related to plasma MMP-9 levels.

Originele taal-2English
Pagina's (van-tot)177-180
Aantal pagina's4
TijdschriftJournal of the Renin-Angiotensin-Aldosterone System
Nummer van het tijdschrift4
StatusPublished - dec-2007

Citeer dit